Skip to main content

Table 1 Demographic and clinical characteristics of children with cerebral malaria included in the final analysed population

From: Plasmodium falciparum clearance time in Malawian children with cerebral malaria: a retrospective cohort study

Demographic, clinical, outcome measure Anti-malarial P value for difference
Quinine-treated (2010–2013) (n = 259) Artesunate-treated (2014–2019) (n = 206)
Age (months): mean, SD 50.9 (28.1) 49.9 (29.8) 0.711
Gender: N male (% male) 136 (52.5) 109 (52.9) 1.000
Splenomegaly (%) 33.6 22.3a 0.009
Glucose mmoL/L: mean (SD) 7.08 (3.49) 6.14 (2.84)b 0.002
Haematocrit (admission) mean (SD) 22.6 (6.45)c 23.8 (6.74) 0.052
Parasites/µl: mean (SD) 260,872 (458,810) 187,612 (278,800)  
Log (parasites): mean (SD) 11.48 (1.63) 10.84 (1.94)  < 0.001
HRP-2 (ng/ml): mean (SD) 7,909 (10,028) 5441 (10,693)  
Log (HRP-2): mean (SD) 7.30 (2.65) 6.96 (2.23) 0.001
Pre-treatment with anti-malarial (%) 222 (85.7) 180 (87.4) 0.70
Blantyre Coma Score: N (%)    0.18
 0 22 (8.5) 26 (12.6)
 1 103 (39.8) 68 (33.0)
 2 134 (51.7) 112 (54.4)
Outcomesd    0.732
 Died: N (%) 46 (17.8) 30 (14.6)
 Neurological sequelae at hospital discharge: N (%) 21 (8.1) 16 (7.8)
 Full recovery: N (%) 188 (72.6) 158 (76.7)
  1. HRP-2 histidine rich protein 2. Variables compared using t-test for continuous variables and Chi-squared tests for categorical variables. P < 0.05 was considered statistically significant
  2. an = 205
  3. bn = 204
  4. cn = 258
  5. dn = 255 in quinine era and 204 in artesunate era